Based on this proof of concept study, we screened a library of FDA-approved drugs in ERα-expressing ductal carcinoma cells (MCF-7) [14] and found the unsuspected role of Tel as a compound that reduces ERα levels and prevents basal and E2-induced cell proliferation. Here, ESR1 is linked to breast ductal adenocarcinoma.